Direct modification of the 5-HT3 receptor current by some anticancer drugs

The serotonin (5-hydroxytryptamine) type 3 (5-HT3) receptor is an important target in the control of emesis, and 5-HT3 receptor antagonists are effective against the early phase chemotherapy evoked vomiting. We recently reported that the anticancer drugs irinotecan and topotecan directly modulate th...

Full description

Saved in:
Bibliographic Details
Published in:European journal of pharmacology 2018-02, Vol.821, p.21-28
Main Authors: Nakamura, Yukiko, Ishida, Yusuke, Kondo, Makoto, Shimada, Shoichi
Format: Article
Language:English
Subjects:
5-HT3A
5-HT3B
Anticancer drug
Emesis
Modulator
Vomiting
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c405t-7aa3979abe47a74a774d4dd3ad0b7751adca3aef52fd8622aec0af5b85b27f193
cites cdi_FETCH-LOGICAL-c405t-7aa3979abe47a74a774d4dd3ad0b7751adca3aef52fd8622aec0af5b85b27f193
container_end_page 28
container_issue
container_start_page 21
container_title European journal of pharmacology
container_volume 821
creator Nakamura, Yukiko
Ishida, Yusuke
Kondo, Makoto
Shimada, Shoichi
description The serotonin (5-hydroxytryptamine) type 3 (5-HT3) receptor is an important target in the control of emesis, and 5-HT3 receptor antagonists are effective against the early phase chemotherapy evoked vomiting. We recently reported that the anticancer drugs irinotecan and topotecan directly modulate the 5-HT-mediated 5-HT3 receptor current in vitro. In addition, the drug response depends on the 5-HT3 subunit composition. Here, we explored the effects of 35 anticancer drugs on the 5-HT3 receptor current. We microinjected Xenopus laevis oocytes with human 5-HT3A cRNA or a combination of human 5-HT3A and human 5-HT3B cRNA, and performed two-electrode voltage clamp recordings of 5-HT3A and 5-HT3AB receptor currents in the presence of each of the 35 drugs. Over 25% of the drugs we tested inhibited or potentiated the 5-HT3 receptor current. The drugs that modulated the 5-HT3 receptor current had molecular weights of approximately 500. These results implied that these anticancer drugs could affect 5-HT3 receptor.
doi_str_mv 10.1016/j.ejphar.2017.12.054
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1980542520</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0014299917308543</els_id><sourcerecordid>1980542520</sourcerecordid><originalsourceid>FETCH-LOGICAL-c405t-7aa3979abe47a74a774d4dd3ad0b7751adca3aef52fd8622aec0af5b85b27f193</originalsourceid><addsrcrecordid>eNp9kD1PwzAURS0EEqXwDxg8siTYTlzHCxIqHwVVYimz9WK_UEdtXGwXiX9PSpmZ3vDuudI9hFxzVnLGZ7d9if1uDbEUjKuSi5LJ-oRMeKN0wRQXp2TCGK8LobU-Jxcp9YwxqYWckNcHH9Fmug3Od95C9mGgoaN5jVQWi1VFxzfucojU7mPEIdP2m6awRQpDHoHBYqQu7j_SJTnrYJPw6u9OyfvT42q-KJZvzy_z-2VhayZzoQAqrTS0WCtQNShVu9q5ChxrlZIcnIUKsJOic81MCEDLoJNtI1uhOq6rKbk59u5i-Nxjymbrk8XNBgYM-2S4bsb9Qgo2Rutj1MaQUsTO7KLfQvw2nJmDOtObozpzUGe4MCM6YndHDMcZXx6jSdbjuNT9yjIu-P8LfgBUtXnK</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1980542520</pqid></control><display><type>article</type><title>Direct modification of the 5-HT3 receptor current by some anticancer drugs</title><source>Elsevier:Jisc Collections:Elsevier Read and Publish Agreement 2022-2024:Freedom Collection (Reading list)</source><creator>Nakamura, Yukiko ; Ishida, Yusuke ; Kondo, Makoto ; Shimada, Shoichi</creator><creatorcontrib>Nakamura, Yukiko ; Ishida, Yusuke ; Kondo, Makoto ; Shimada, Shoichi</creatorcontrib><description>The serotonin (5-hydroxytryptamine) type 3 (5-HT3) receptor is an important target in the control of emesis, and 5-HT3 receptor antagonists are effective against the early phase chemotherapy evoked vomiting. We recently reported that the anticancer drugs irinotecan and topotecan directly modulate the 5-HT-mediated 5-HT3 receptor current in vitro. In addition, the drug response depends on the 5-HT3 subunit composition. Here, we explored the effects of 35 anticancer drugs on the 5-HT3 receptor current. We microinjected Xenopus laevis oocytes with human 5-HT3A cRNA or a combination of human 5-HT3A and human 5-HT3B cRNA, and performed two-electrode voltage clamp recordings of 5-HT3A and 5-HT3AB receptor currents in the presence of each of the 35 drugs. Over 25% of the drugs we tested inhibited or potentiated the 5-HT3 receptor current. The drugs that modulated the 5-HT3 receptor current had molecular weights of approximately 500. These results implied that these anticancer drugs could affect 5-HT3 receptor.</description><identifier>ISSN: 0014-2999</identifier><identifier>EISSN: 1879-0712</identifier><identifier>DOI: 10.1016/j.ejphar.2017.12.054</identifier><language>eng</language><publisher>Elsevier B.V</publisher><subject>5-HT3A ; 5-HT3B ; Anticancer drug ; Emesis ; Modulator ; Vomiting</subject><ispartof>European journal of pharmacology, 2018-02, Vol.821, p.21-28</ispartof><rights>2017 Elsevier B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c405t-7aa3979abe47a74a774d4dd3ad0b7751adca3aef52fd8622aec0af5b85b27f193</citedby><cites>FETCH-LOGICAL-c405t-7aa3979abe47a74a774d4dd3ad0b7751adca3aef52fd8622aec0af5b85b27f193</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Nakamura, Yukiko</creatorcontrib><creatorcontrib>Ishida, Yusuke</creatorcontrib><creatorcontrib>Kondo, Makoto</creatorcontrib><creatorcontrib>Shimada, Shoichi</creatorcontrib><title>Direct modification of the 5-HT3 receptor current by some anticancer drugs</title><title>European journal of pharmacology</title><description>The serotonin (5-hydroxytryptamine) type 3 (5-HT3) receptor is an important target in the control of emesis, and 5-HT3 receptor antagonists are effective against the early phase chemotherapy evoked vomiting. We recently reported that the anticancer drugs irinotecan and topotecan directly modulate the 5-HT-mediated 5-HT3 receptor current in vitro. In addition, the drug response depends on the 5-HT3 subunit composition. Here, we explored the effects of 35 anticancer drugs on the 5-HT3 receptor current. We microinjected Xenopus laevis oocytes with human 5-HT3A cRNA or a combination of human 5-HT3A and human 5-HT3B cRNA, and performed two-electrode voltage clamp recordings of 5-HT3A and 5-HT3AB receptor currents in the presence of each of the 35 drugs. Over 25% of the drugs we tested inhibited or potentiated the 5-HT3 receptor current. The drugs that modulated the 5-HT3 receptor current had molecular weights of approximately 500. These results implied that these anticancer drugs could affect 5-HT3 receptor.</description><subject>5-HT3A</subject><subject>5-HT3B</subject><subject>Anticancer drug</subject><subject>Emesis</subject><subject>Modulator</subject><subject>Vomiting</subject><issn>0014-2999</issn><issn>1879-0712</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9kD1PwzAURS0EEqXwDxg8siTYTlzHCxIqHwVVYimz9WK_UEdtXGwXiX9PSpmZ3vDuudI9hFxzVnLGZ7d9if1uDbEUjKuSi5LJ-oRMeKN0wRQXp2TCGK8LobU-Jxcp9YwxqYWckNcHH9Fmug3Od95C9mGgoaN5jVQWi1VFxzfucojU7mPEIdP2m6awRQpDHoHBYqQu7j_SJTnrYJPw6u9OyfvT42q-KJZvzy_z-2VhayZzoQAqrTS0WCtQNShVu9q5ChxrlZIcnIUKsJOic81MCEDLoJNtI1uhOq6rKbk59u5i-Nxjymbrk8XNBgYM-2S4bsb9Qgo2Rutj1MaQUsTO7KLfQvw2nJmDOtObozpzUGe4MCM6YndHDMcZXx6jSdbjuNT9yjIu-P8LfgBUtXnK</recordid><startdate>20180215</startdate><enddate>20180215</enddate><creator>Nakamura, Yukiko</creator><creator>Ishida, Yusuke</creator><creator>Kondo, Makoto</creator><creator>Shimada, Shoichi</creator><general>Elsevier B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20180215</creationdate><title>Direct modification of the 5-HT3 receptor current by some anticancer drugs</title><author>Nakamura, Yukiko ; Ishida, Yusuke ; Kondo, Makoto ; Shimada, Shoichi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c405t-7aa3979abe47a74a774d4dd3ad0b7751adca3aef52fd8622aec0af5b85b27f193</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>5-HT3A</topic><topic>5-HT3B</topic><topic>Anticancer drug</topic><topic>Emesis</topic><topic>Modulator</topic><topic>Vomiting</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nakamura, Yukiko</creatorcontrib><creatorcontrib>Ishida, Yusuke</creatorcontrib><creatorcontrib>Kondo, Makoto</creatorcontrib><creatorcontrib>Shimada, Shoichi</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nakamura, Yukiko</au><au>Ishida, Yusuke</au><au>Kondo, Makoto</au><au>Shimada, Shoichi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Direct modification of the 5-HT3 receptor current by some anticancer drugs</atitle><jtitle>European journal of pharmacology</jtitle><date>2018-02-15</date><risdate>2018</risdate><volume>821</volume><spage>21</spage><epage>28</epage><pages>21-28</pages><issn>0014-2999</issn><eissn>1879-0712</eissn><abstract>The serotonin (5-hydroxytryptamine) type 3 (5-HT3) receptor is an important target in the control of emesis, and 5-HT3 receptor antagonists are effective against the early phase chemotherapy evoked vomiting. We recently reported that the anticancer drugs irinotecan and topotecan directly modulate the 5-HT-mediated 5-HT3 receptor current in vitro. In addition, the drug response depends on the 5-HT3 subunit composition. Here, we explored the effects of 35 anticancer drugs on the 5-HT3 receptor current. We microinjected Xenopus laevis oocytes with human 5-HT3A cRNA or a combination of human 5-HT3A and human 5-HT3B cRNA, and performed two-electrode voltage clamp recordings of 5-HT3A and 5-HT3AB receptor currents in the presence of each of the 35 drugs. Over 25% of the drugs we tested inhibited or potentiated the 5-HT3 receptor current. The drugs that modulated the 5-HT3 receptor current had molecular weights of approximately 500. These results implied that these anticancer drugs could affect 5-HT3 receptor.</abstract><pub>Elsevier B.V</pub><doi>10.1016/j.ejphar.2017.12.054</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0014-2999
ispartof European journal of pharmacology, 2018-02, Vol.821, p.21-28
issn 0014-2999
1879-0712
language eng
recordid cdi_proquest_miscellaneous_1980542520
source Elsevier:Jisc Collections:Elsevier Read and Publish Agreement 2022-2024:Freedom Collection (Reading list)
subjects 5-HT3A
5-HT3B
Anticancer drug
Emesis
Modulator
Vomiting
title Direct modification of the 5-HT3 receptor current by some anticancer drugs
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T21%3A14%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Direct%20modification%20of%20the%205-HT3%20receptor%20current%20by%20some%20anticancer%20drugs&rft.jtitle=European%20journal%20of%20pharmacology&rft.au=Nakamura,%20Yukiko&rft.date=2018-02-15&rft.volume=821&rft.spage=21&rft.epage=28&rft.pages=21-28&rft.issn=0014-2999&rft.eissn=1879-0712&rft_id=info:doi/10.1016/j.ejphar.2017.12.054&rft_dat=%3Cproquest_cross%3E1980542520%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c405t-7aa3979abe47a74a774d4dd3ad0b7751adca3aef52fd8622aec0af5b85b27f193%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1980542520&rft_id=info:pmid/&rfr_iscdi=true